Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
236.12
-1.85 (-0.78%)
Dec 30, 2024, 12:08 PM EST - Market open
Alnylam Pharmaceuticals Employees
Alnylam Pharmaceuticals had 2,100 employees as of December 31, 2023. The number of employees increased by 98 or 4.90% compared to the previous year.
Employees
2,100
Change (1Y)
98
Growth (1Y)
4.90%
Revenue / Employee
$997,521
Profits / Employee
-$158,221
Market Cap
30.45B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2,100 | 98 | 4.90% |
Dec 31, 2022 | 2,002 | 337 | 20.24% |
Dec 31, 2021 | 1,665 | 212 | 14.59% |
Dec 31, 2020 | 1,453 | 130 | 9.83% |
Dec 31, 2019 | 1,323 | 258 | 24.23% |
Dec 31, 2018 | 1,065 | 316 | 42.19% |
Dec 31, 2017 | 749 | 235 | 45.72% |
Dec 31, 2016 | 514 | 145 | 39.30% |
Dec 31, 2015 | 369 | 113 | 44.14% |
Dec 31, 2014 | 256 | 91 | 55.15% |
Dec 31, 2013 | 165 | 36 | 27.91% |
Dec 31, 2012 | 129 | 13 | 11.21% |
Dec 31, 2011 | 116 | -56 | -32.56% |
Dec 31, 2010 | 172 | -6 | -3.37% |
Dec 31, 2009 | 178 | 8 | 4.71% |
Dec 31, 2008 | 170 | 41 | 31.78% |
Dec 31, 2007 | 129 | 7 | 5.74% |
Dec 31, 2006 | 122 | 28 | 29.79% |
Dec 31, 2005 | 94 | 23 | 32.39% |
Dec 31, 2004 | 71 | 11 | 18.33% |
Dec 31, 2003 | 60 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
ALNY News
- 4 weeks ago - Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference - Business Wire
- 5 weeks ago - Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy - Business Wire
- 6 weeks ago - Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose - Business Wire
- 2 months ago - Alnylam to Webcast Presentations at Upcoming November Investor Conferences - Business Wire
- 2 months ago - Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity - Business Wire
- 2 months ago - Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024 - Business Wire
- 2 months ago - Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch - Seeking Alpha